On June 29, WuXi Biologics rose 3.39% in regular trading, reaching HK$34.4 per share, with turnover of HK$254 million.

On the news front, the company has maintained a high-frequency buyback pace, executing on-market repurchases nearly every trading day since early June, with single-day amounts ranging from approximately HK$50 million to HK$100 million. The buyback authorization approved at the June 10 shareholders meeting allows repurchases of up to approximately 412 million shares. Additionally, the company's 25th drug substance manufacturing facility recently completed its first GMP production batch with zero deviations, signaling continued capacity expansion.

Within the Life Sciences Tools and Services sector, broad-based strength was evident. Among individual stocks, XtalPi rose 6.96%, Pharmaron rose 4.86%, WuXi AppTec rose 3.37%, WuXi XDC rose 3.36%, while Insilico declined 1.05%, reflecting significant sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)